Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 4/20 | 0.33 |
| ▸ | CTSK | P43235 | 4/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.30 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111032 | 0.81 | CTSK (0.36) | MEN1GAAKMT2ACTSSCTSK | |
| SCHEMBL843624 | 0.79 | MAPT (0.32) | — | |
| SCHEMBL2468050 | 0.71 | MEN1 (0.52) | MEN1KMT2ACTSSCA12CA2 | |
| SCHEMBL2923540 | 0.70 | DGAT1 (0.38) | MEN1GAAKMT2ADGAT1CTSS | |
| SCHEMBL25229366 | 0.70 | MEN1 (0.44) | MEN1GAAKMT2ADGAT1CTSS | |
| SCHEMBL2512445 | 0.70 | MEN1 (0.40) | MEN1GAAKMT2ADGAT1CTSS | |
| SCHEMBL76832 | 0.70 | KDM4C (0.41) | MEN1GAAKMT2ADGAT1CTSS | |
| SCHEMBL16296168 | 0.69 | KDM4C (0.39) | MEN1GAAKMT2ADGAT1CTSS | |
| SCHEMBL25811478 | 0.69 | CTSK (0.41) | MEN1GAAKMT2ADGAT1CTSS | |
| SCHEMBL21834933 | 0.69 | KDM4C (0.39) | MEN1GAAKMT2ADGAT1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3049394-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-03 | — | — | EP | disclosed |
| WO-2015044167-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AS MODULATORS OF FACTOR XIA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| EP-1675835-B1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR ON SOLID SUPPORTED PHASE | PRO ACTINA S A (GR) | 2011-09-21 | — | — | EP | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| EP-1697400-B1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO KG (DE) | 2011-05-25 | — | — | EP | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| US-7129249-B2 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| EP-1697400-A1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AiCuris GmbH & Co. KG (DE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1675835-A1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR OF SOLID SUPPORTED PHASE | Couladouros, Elias Andrea (GR) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005058943-A1 | BIPHENYL-SUBSTITUTED ANTIBACTERIAL MACROCYCLES | AICURIS GMBH & CO. KG (DE) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| WO-2005003102-A1 | METHODS OF PREPARATION OF DEHYDRO-DIKETOPIPERAZINES IN LIQUID PHASE OR OF SOLID SUPPORTED PHASE | COULADOUROS ELIAS (GR) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131015-A1 | Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase | PYGL, GYS2, GYS1 | MEN1 3701/4885GAA 59/4885KMT2A 3909/4885 |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | MEN1 1768/4885GAA 279/4885KMT2A 1856/4885 |
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | MEN1 2942/4885GAA 2573/4885KMT2A 911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.